TIP30在 HER-2阳性乳腺癌患者癌组织中的表达及临床意义

目的：探讨TIP30在表皮生长因子受体-2（HER-2）阳性乳腺癌患者癌组织中表达及临床意义。方法选择接受过生物化疗（曲妥珠单抗联合紫杉醇）的HER-2阳性晚期乳腺癌患者53例，采用免疫组化法检测患者癌组织中的TIP30表达，并分析其表达与患者临床病理特征及临床疗效的关系。结果 TIP30在HER-2阳性乳腺癌组织中阳性表达率为56．6％，TIP30表达与患者的年龄、病理类型、转移部位数量及雌激素受体、孕激素受体表达无关，而与功能状态评分及临床疗效相关（P均＜0．05）。53例患者化疗2个周期后，临床获益（CB）29例（CB率为54．7％）。30例TIP30阳性表达的患者中，CB 22例（73．3％）；23例TIP30阴性表达的患者中，CB 7例（30．4％），两者CB率比较P＜0．05。 TIP30表达阳性、阴性患者的中位无进展生存期分别为11．47、4．87个月，两者比较P＜0．01。结论 TIP30在HER-2阳性晚期乳腺癌患者癌组织中表达下调可能与预后不良有关，其可能作为该类患者生物化疗的疗效预测指标之一。

Expression of TIP30 in HER-2-positive advanced breast cancer tissues and its clinical significance

Objective To explore the expression of TIP 30 in epidermal growth factor receptor-2 （ HER-2 ）-positive advanced breast cancer and its clinical significance. Me thods The expression of TIP30 was detected in 53 HER-2-positive advanced breast cancer tissues by immunohistochemistry .The tissues were obtained before biochemotherapy by Herceptin plus taxol （ TAX） .The relationship with clinicopathological parameters and biochemotherapy response was analyzed .Re-sults The positive expression rate of TIP30 was 56.6%in HER-2-positive advanced breast cancer tissues .There was no correlation between the expression of TIP30 protein and age, pathological pattern, metastasis, estrogen receptor （ER）, and progestrone receptor （ PR） , but the expression of TIP 30 was associated with the functional status score and clinical efficacy （all P〈0.05）.After two cycles of biochemotherapy , the clinical benefit rate （CBR） was 54.7%.In 30 patients with positive TIP30 expression, the CBR was 73.3%（22/30）, by contrast, the CBR was only 30.4%in 23 patients with neg-ative TIP30 expression, which showed a significant difference between the two groups （all P〈0.05）.The median progres-sion-free survival time was 11.47 and 4.87 months in patients with positive TIP30 expression and negative TIP30 expres-sion, respectively （all P〈0.01）.Conclusion The down-regulated TIP30 expression in HER-2-positive advanced breast cancer may be associated with the poor prognosis , which could be an important biomarker in predicting the efficacy of bio-chemotherapy in patients with HER-2-positive advanced breast cancer .